NSE filing, NSE: KILITCH. Summary written from the filing by ALFA Finder's alert engine.
Kilitch Drugs(I) Ltd: key numbers
- Share price
- ₹201.32
- Market cap
- ₹703.9 Cr
- Revenue (annual)
- ₹235.5 Cr
- Net profit (annual)
- ₹30.17 Cr
- P/E (TTM)
- 23.4×Sector 45.9×
- Promoter holding
- 63.77%+0.00% QoQ
- FII holding
- 0.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kilitch Drugs(I) Ltd
All →Kilitch Drugs(I) Annual General Meeting
Kilitch Drugs' EGM notice seeks shareholder approval for selling its Ethiopian material subsidiary and converting subsidiary debt into equity. It also proposes two independent director appointments.
Kilitch Drugs(I) Merger & Restructuring Worth ₹131.6 Cr
Kilitch Drugs will divest its entire Ethiopian subsidiary stake to HarmeeCare for US$14 million (~₹131.6 Crore). Proceeds will fund debt repayment and Pen plant expansion.
- Value
- ₹131.6 Cr
Kilitch Drugs(I) Merger & Restructuring Worth ₹120.8 Cr
Kilitch Drugs will divest its 100% stake in subsidiary Kilitch Estro Biotech PLC for USD 12.855 million (approx. ₹120.84 Crore).
- Value
- ₹120.8 Cr
- From
- HarmeeCare Pharmaceuticals
Kilitch Drugs(I) Management Change
Kilitch Drugs' Non-Executive Independent Director Mr. Venkita Subramanian Rajan resigned effective 21 Oct 2026. He also stepped down from the Audit, NCR, and SRC Committees citing personal commitments.
Kilitch Drugs(I) Annual General Meeting
Kilitch Drugs (India) held its 34th Annual General Meeting on August 27, 2026, transacting four business resolutions including financial statement approval and director re-appointment.
Kilitch Drugs(I) Other Announcement
Kilitch Drugs filed its Monitoring Agency Report for the quarter ended June 30, 2026, concerning its Rights Issue proceeds of Rs. 49.92 Crore.
- Value
- ₹49.92 Cr
Other other announcement announcements
All →GAMCO Other Announcement
Gamco Ltd filed its half-yearly related party transactions disclosure under Regulation 23(9) for the period ended 30 September 2026. The filing is a periodic cumulative statement with no new transaction or board decision.
- Execution
- Half year ended 30 September 2026
Repono Other Announcement
Repono Ltd filed its half-yearly shareholding pattern as of September 30, 2026. Promoter and promoter group hold 72.47% of shares, a routine compliance disclosure.
Shanthala FMCG Products Other Announcement
Shanthala FMCG declared Regulation 23 related party transaction disclosures do not apply for the year ended 31 March 2026. The company is SME-listed and below the threshold.
Mitsu Chem Plast Other Announcement
Mitsu Chem Plast reported that its statutory auditor, Gokhale & Sathe, converted into Gokhale & Sathe LLP effective 27 August 2026. The engagement and tenure remain unchanged.
Sonu Infratech Other Announcement
Sonu Infratech reported full utilisation of Rs.551.24 lakh raised from warrant conversion, with no deviation. The Audit Committee reviewed the statement and auditors issued no comments.
DOMS Industries Other Announcement
DOMS Industries filed its quarterly shareholding pattern for the period ended 30 September 2026. It is a periodic statement with no transaction or reclassification.